CES 2016: Consumer and Medical Devices Come Together in Digital Health

The role digital health will ultimately play in the overall health care market is still evolving, but it is becoming clearer that consumers and consumer-based products will play a role. The merging of consumer and medical was evident at CES in Las Vegas, where an increasing number of businesses are showcasing new products for the digital health market, which is expected to reach $233 billion by 2020.

Although it is still a young market, the digital health care space has evolved to the point where it seems an increasing number of businesses are regularly jumping into the arena in an effort to establish themselves in what is predicted to be the next big wave in health care delivery. (SeeAlso see "The Digital Health Care Revolution Picks Up Speed" - Medtech Insight, 14 July, 2015..) Given that the overall digital health market is expected to nearly quadruple to $233 billion by 2020, the financial incentives are clear. Accompanying these businesses is technology that comes either in the form of a new medical product, or a new take on an existing product, and as the market develops, boundaries and rules that affect all of health care are changing. Those technologies and changes were on display in January at CES 2016, the Consumer Electronics Show, in Las Vegas, hosted by the Consumer Technology Association, and also at the two-day Seventh Annual Digital Health Summit at CES.

The New Digital Health Ecosystem

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By 

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By 

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.